Cargando…
Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score
BACKGROUND: This study aimed to evaluate the predictive value of systemic inflammation response index (SIRI) in primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) patients and establish a highly discriminating risk prediction model. METHODS: This retrospective analysis included 153 P...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166949/ https://www.ncbi.nlm.nih.gov/pubmed/36866830 http://dx.doi.org/10.1002/cam4.5733 |
_version_ | 1785038555336146944 |
---|---|
author | Chu, Yurou Liu, Yingyue Jiang, Yujie Ge, Xueling Yuan, Dai Ding, Mei Qu, Huiting Liu, Fang Zhou, Xiangxiang Wang, Xin |
author_facet | Chu, Yurou Liu, Yingyue Jiang, Yujie Ge, Xueling Yuan, Dai Ding, Mei Qu, Huiting Liu, Fang Zhou, Xiangxiang Wang, Xin |
author_sort | Chu, Yurou |
collection | PubMed |
description | BACKGROUND: This study aimed to evaluate the predictive value of systemic inflammation response index (SIRI) in primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) patients and establish a highly discriminating risk prediction model. METHODS: This retrospective analysis included 153 PGI‐DCBCL patients diagnosed between 2011 and 2021. These patients were divided into a training set (n = 102) and a validation set (n = 51). Univariate and multivariate Cox regression analyses were conducted to examine the significance of variables on overall survival (OS) and progression‐free survival (PFS). An inflammation‐covered score system was established according to the multivariate results. RESULTS: The presence of high pretreatment SIRI (≥1.34, p < 0.001) was significantly associated with poorer survival and identified as an independent prognostic factor. Compared with NCCN‐IPI, the prognostic and discriminatory capability of the novel model SIRI‐PI showed a more precise high‐risk assessment with a higher area under the curve (AUC) (0.916 vs 0.835) and C‐index (0.912 vs 0.836) for OS in the training cohort, and similar results were obtained in the validation cohort. Moreover, SIRI‐PI also showed good discriminative power for efficacy assessment. This new model identified patients at risk of developing severe gastrointestinal complications following chemotherapy. CONCLUSIONS: The results of this analysis suggested that the pretreatment SIRI may be a potential candidate for identifying patients with a poor prognosis. And we established and validated a better‐performing clinical model, which facilitated the prognostic stratification of PGI‐DLBCL patients and can serve as a reference for clinical decision‐making. |
format | Online Article Text |
id | pubmed-10166949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101669492023-05-10 Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score Chu, Yurou Liu, Yingyue Jiang, Yujie Ge, Xueling Yuan, Dai Ding, Mei Qu, Huiting Liu, Fang Zhou, Xiangxiang Wang, Xin Cancer Med RESEARCH ARTICLES BACKGROUND: This study aimed to evaluate the predictive value of systemic inflammation response index (SIRI) in primary gastrointestinal diffuse large B‐cell lymphoma (PGI‐DLBCL) patients and establish a highly discriminating risk prediction model. METHODS: This retrospective analysis included 153 PGI‐DCBCL patients diagnosed between 2011 and 2021. These patients were divided into a training set (n = 102) and a validation set (n = 51). Univariate and multivariate Cox regression analyses were conducted to examine the significance of variables on overall survival (OS) and progression‐free survival (PFS). An inflammation‐covered score system was established according to the multivariate results. RESULTS: The presence of high pretreatment SIRI (≥1.34, p < 0.001) was significantly associated with poorer survival and identified as an independent prognostic factor. Compared with NCCN‐IPI, the prognostic and discriminatory capability of the novel model SIRI‐PI showed a more precise high‐risk assessment with a higher area under the curve (AUC) (0.916 vs 0.835) and C‐index (0.912 vs 0.836) for OS in the training cohort, and similar results were obtained in the validation cohort. Moreover, SIRI‐PI also showed good discriminative power for efficacy assessment. This new model identified patients at risk of developing severe gastrointestinal complications following chemotherapy. CONCLUSIONS: The results of this analysis suggested that the pretreatment SIRI may be a potential candidate for identifying patients with a poor prognosis. And we established and validated a better‐performing clinical model, which facilitated the prognostic stratification of PGI‐DLBCL patients and can serve as a reference for clinical decision‐making. John Wiley and Sons Inc. 2023-03-03 /pmc/articles/PMC10166949/ /pubmed/36866830 http://dx.doi.org/10.1002/cam4.5733 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Chu, Yurou Liu, Yingyue Jiang, Yujie Ge, Xueling Yuan, Dai Ding, Mei Qu, Huiting Liu, Fang Zhou, Xiangxiang Wang, Xin Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score |
title | Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score |
title_full | Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score |
title_fullStr | Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score |
title_full_unstemmed | Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score |
title_short | Prognosis and complications of patients with primary gastrointestinal diffuse large B‐cell lymphoma: Development and validation of the systemic inflammation response index‐covered score |
title_sort | prognosis and complications of patients with primary gastrointestinal diffuse large b‐cell lymphoma: development and validation of the systemic inflammation response index‐covered score |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166949/ https://www.ncbi.nlm.nih.gov/pubmed/36866830 http://dx.doi.org/10.1002/cam4.5733 |
work_keys_str_mv | AT chuyurou prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT liuyingyue prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT jiangyujie prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT gexueling prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT yuandai prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT dingmei prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT quhuiting prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT liufang prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT zhouxiangxiang prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore AT wangxin prognosisandcomplicationsofpatientswithprimarygastrointestinaldiffuselargebcelllymphomadevelopmentandvalidationofthesystemicinflammationresponseindexcoveredscore |